Through the deal, Celgene gains Gloucester's romidepsin (Istodax), a histone deacetylase (HDAC) inhibitor, which was approved by the FDA in November 2009 to treat cutaneous T cell lymphoma (CTCL ...

Concerns about HA-based HDAC inhibitors such as genotoxicity, rapid clearance and extensive metabolite formation, led CKD’s research team to identify a series of NHA molecules that selectively ...

“Issuance of the new patent for our oncology preclinical aPKCi inhibitor pipeline is an important part of our development strategy,” said Jed Latkin, CEO of Windtree Therapeutics. “We will continue ...

Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative ...

Cash-strapped Viracta Therapeutics is continuing to reduce its options in order to stay afloat. Less than two months after ...

Wigen Biomedicine Technology (Shanghai) Co. Ltd. has divulged compounds acting as histone deacetylase 1 (HDAC1) and/or 2 (HDAC2) inhibitors reported to be useful for the treatment of cancer.

In contrast, in the new trial combining an HDAC inhibitor with the immunotherapy, 3 of 27 patients had deep tumor shrinkage from the drug combination. In future studies, the team hopes to ...

The CUDC-907 pipeline is an orally available small molecule inhibitor of HDAC and PI3K enzymes. The CA-170 pipeline is an also an orally-available small molecule antagonist of PD-L1 and VISTA ...